Skip to main content
  • Olympus may acquire Israeli Medical Device Company Medi-Tate

    Olympus made its initial investment in Medi-Tate in November 2018, under an agreement that included the rights to distribute Medi-Tate products and gave Olympus an option to acquire 100% of the Israeli company at a later date. Medi-Tate is a medical device manufacturer engaged in the research and development, production, and sale of devices for the minimally invasive treatment of benign prostatic hyperplasia (“BPH”). The company’s flagship product “iTind” has received a European CE mark and is FDA cleared for use in the U.S.

  • Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan

    Takeda Pharmaceutical Company Limited announced that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan. Earlier this month, Takeda completed enrollment in the company’s Phase 1/2 immunogenicity and safety study of Moderna’s COVID-19 vaccine candidate (TAK-919) in Japan.

  • Laipac Technology to Launch World’s First AI Rapid Antigen Test System

    The LooK SPOT solution is an intelligent and innovative way to deploy technologies to better protect the health of people across the region. Being able to have a quick and accurate COVID-19 diagnosis can interrupt transmission, aid clinical management, and help proper allocation of resources to isolation.

  • Smiths Detection's BioFlash shown to detect airborne COVID-19

    Smiths Detection, a global leader in threat detection and security screening technologies, reports that its BioFlash® Biological Identifier is capable of detecting SARS-CoV-2 in the air following tests conducted by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).

  • Xech Designs India’s First Stethoscope Sterilizer

    XECH, India’s emerging innovator brand, has launched XECH STEROSTET – one-of-its-kind and India’s first Stethoscope Sterilizer which uses a special UV-C GI Technology to effectively sterilize stethoscopes diaphragms of all sizes up to 99.9999%.

  • Takeda submits NDA for a drug uitlised in Perianal Fistulas in Crohn’s disease at Japan

    Takeda Pharmaceutical Company Limited announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darvadstrocel (development code: Cx601) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease (CD).

  • Umbralisib has received US FDA accelerated approval for relapsed or refractory lymphomas

    Rhizen Pharmaceuticals, a clinical-stage oncology-focused biopharmaceutical company, announced that its novel next generation PI3K-delta inhibitor, Umbralisib, which was licensed to TG Therapeutics has secured USFDA accelerated approval for the treatment of : (1) adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 based regimen, and (2) adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.

  • Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis

    Mundipharma and Cidara Therapeutics announced that the European Commission (EC) has now adopted the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) recommendation to grant Orphan Drug Designation (ODD) to rezafungin, a novel, once-weekly echinocandin, for the treatment of invasive candidiasis (IC).

  • World Health Organization Grants Prequalification to Bharat Biotech's Rotavirus Vaccine, ROTAVAC

    Pharma courses

    pharma courses

    Bharat Biotech announced that the World Health Organization (WHO Geneva) has awarded prequalification to the developing world’s first rotavirus vaccine, ROTAVAC®.

  • Nemaura Pharma secures funding to advance its Micro-Patch™ solid dose microneedle system for a hormone Biologic

    Pharma courses

    pharma courses

    UK biotech company Nemaura Pharma has announced a commitment from private investors of up to £5m for the development of a hormone Biologic using its Micro-Patch™ solid dose delivery platform. The fast-growing company has made significant progress in the reformulation of liquid vaccines administered through the skin using its solid dose delivery system. The funding is being used to accelerate Nemaura’s commercial research and development of clinical programmes to prepare the drug-device combination for market.

Subscribe to Business Wire India